These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 26398237)

  • 21. Clinician Ordering and Management Patterns of Urine Toxicology Results at a Cancer Center.
    Yusufov M; Melanson SEF; Kang P; Kematick B; Schiff GD; Chua IS
    J Pain Symptom Manage; 2024 Jul; 68(1):e36-e45. PubMed ID: 38599533
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Urine Drug Testing in Cancer Pain Management.
    Arthur JA
    Oncologist; 2020 Feb; 25(2):99-104. PubMed ID: 32043770
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Physician Renewal of Chronically Prescribed Controlled Substances Based on Urine Drug Test Results.
    Hosain F; Lee J; Ata A; Bhullar RK; Chang AK
    J Prim Care Community Health; 2019; 10():2150132719883632. PubMed ID: 31646927
    [No Abstract]   [Full Text] [Related]  

  • 24. Urine Drug Testing Among Patients Prescribed Long-Term Opioid Therapy: Patient and Clinician Factors.
    Agnoli AL; Howe R; Magnan E; Jerant A; Colby D; Franks P
    J Am Board Fam Med; 2023 Aug; 36(4):537-541. PubMed ID: 37468213
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Utility of the Pain Medication Questionnaire to predict aberrant urine drug tests: Results from a longitudinal cohort study.
    Morasco BJ; Iacocca MO; Lovejoy TI; Dobscha SK; Deyo RA; Cavese JA; Hyde S; Yarborough BJH
    Psychol Serv; 2021 Aug; 18(3):319-327. PubMed ID: 32673038
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Shorter drug testing intervals are associated with improved drug misuse rates.
    Gudin J; Mehta N; McClure FL; Niles JK; Kaufman HW
    J Opioid Manag; 2020 Sep/Oct 2020; 16(5):357-373. PubMed ID: 33226093
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Laboratory-Generated Urine Toxicology Interpretations: A Mixed Methods Study.
    Chua IS; Ransohoff JR; Ehrlich O; Katznelson E; Virk ZM; Demetriou CA; Petrides AK; Orav EJ; Schiff GD; Melanson SEF
    Pain Physician; 2021 Mar; 24(2):E191-E201. PubMed ID: 33740356
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Controlled substance abuse and illicit drug use in chronic pain patients: An evaluation of multiple variables.
    Manchikanti L; Cash KA; Damron KS; Manchukonda R; Pampati V; McManus CD
    Pain Physician; 2006 Jul; 9(3):215-25. PubMed ID: 16886030
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Urine drug testing: current recommendations and best practices.
    Owen GT; Burton AW; Schade CM; Passik S
    Pain Physician; 2012 Jul; 15(3 Suppl):ES119-33. PubMed ID: 22786451
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Utility and application of urine drug testing in chronic pain management with opioids.
    Nafziger AN; Bertino JS
    Clin J Pain; 2009 Jan; 25(1):73-9. PubMed ID: 19158549
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Repeated Quantitative Urine Toxicology Analysis May Improve Chronic Pain Patient Compliance with Opioid Therapy.
    Knezevic NN; Khan OM; Beiranvand A; Candido KD
    Pain Physician; 2017 Feb; 20(2S):S135-S145. PubMed ID: 28226335
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 'False-positive' and 'false-negative' test results in clinical urine drug testing.
    Reisfield GM; Goldberger BA; Bertholf RL
    Bioanalysis; 2009 Aug; 1(5):937-52. PubMed ID: 21083064
    [TBL] [Abstract][Full Text] [Related]  

  • 33. They don't know what they don't know: internal medicine residents' knowledge and confidence in urine drug test interpretation for patients with chronic pain.
    Starrels JL; Fox AD; Kunins HV; Cunningham CO
    J Gen Intern Med; 2012 Nov; 27(11):1521-7. PubMed ID: 22815062
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Urine drug testing in the context of opioid analgesic prescribing for chronic pain: a content analysis of U.S. state laws in 2022.
    Andraka-Christou B; McAvoy E; Gordon AJ; Ohama M; Brach M; Taylor EA; Vaiana M; Saloner B; Stein BD
    Pain Med; 2023 Dec; 24(12):1306-1317. PubMed ID: 37551941
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessment of mass spectrometry-based pain management testing in clinical laboratories across North America.
    Delaney SR; Danso D; Langman LJ; Jannetto PJ
    Clin Biochem; 2020 Nov; 85():49-52. PubMed ID: 32822662
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Correlates of opiate misuse based on aberrant urine drug tests for patients on chronic opiate therapy in a safety-net, academic primary care clinic.
    Bakhai S; Thilagar B; Reynolds JL; Leonard KE
    J Opioid Manag; 2018; 14(1):23-33. PubMed ID: 29508893
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of urine toxicology testing in the management of chronic opioid therapy.
    Katz N; Fanciullo GJ
    Clin J Pain; 2002; 18(4 Suppl):S76-82. PubMed ID: 12479257
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interpreting urine drug tests: prevalence of morphine metabolism to hydromorphone in chronic pain patients treated with morphine.
    Wasan AD; Michna E; Janfaza D; Greenfield S; Teter CJ; Jamison RN
    Pain Med; 2008 Oct; 9(7):918-23. PubMed ID: 18616432
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Using urine drug testing to support healthy boundaries in clinical care.
    Heit HA; Gourlay DL
    J Opioid Manag; 2015; 11(1):7-12. PubMed ID: 25750160
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interpretation of urine drug testing in pain patients.
    Pesce A; West C; Egan City K; Strickland J
    Pain Med; 2012 Jul; 13(7):868-85. PubMed ID: 22494459
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.